

## Endocrine Hypertension

Michael T. McDermott MD  
Director, Endocrinology and Diabetes Practice  
University of Colorado Hospital

### Disclosure

Michael McDermott has no conflict of interest or relationships to disclose in relation to this educational activity.

### Learning Objectives

- Explain the evaluation and management of primary aldosteronism.
- Discuss the evaluation and management of pheochromocytomas and paragangliomas.
- Review the clinical features and evaluation of Cushing's syndrome and Acromegaly.

### Case

A 31 year old man has hypertension which remains elevated on 3 antihypertensive medications. No family history of hypertension. Meds: Ramipril 10 mg, Amlodipine 10 mg, Metoprolol XL 50 mg  
Exam: BP 158/92 P 68 Ht 6'1" Wt 235 lb.

Physical examination is normal otherwise.

Labs: Na 142 mEq/L, K 3.1 mEq/L, Creatinine 0.9 mg/dl

You decide to evaluate for causes of secondary hypertension.

What initial evaluation would have the highest yield?

1. Plasma metanephrines
2. Plasma aldosterone and plasma renin activity
3. 24 hour urine cortisol excretion
4. Renal artery doppler ultrasound

### Case

A 31 year old man has hypertension which remains elevated on 3 antihypertensive medications. No family history of hypertension. Meds: Ramipril 10 mg, Amlodipine 10 mg, Metoprolol XL 50 mg  
Exam: BP 158/92 P 68 Ht 6'1" Wt 235 lb.

Physical examination is normal otherwise.

Labs: Na 142 mEq/L, K 3.1 mEq/L, Creatinine 0.9 mg/dl

Plasma Aldosterone 38 ng/dl (normal: 1-21)

Plasma Renin Activity < 0.6 ng/ml/hr (normal: 0.6-4.3)

What is your interpretation of these results?

1. Diagnostic of primary aldosteronism
2. Possible false positive due to ACE inhibitor
3. Possible false positive due to calcium channel blocker
4. Possible false positive due to beta blocker

### Case

A 31 year old man has hypertension which remains elevated on 3 antihypertensive medications. No family history of hypertension. Meds: Ramipril 10 mg, Amlodipine 10 mg, Metoprolol XL 50 mg  
Exam: BP 158/92 P 68 Ht 6'1" Wt 235 lb.

Physical examination is normal otherwise.

Labs: Na 142 mEq/L, K 3.1 mEq/L, Creatinine 0.9 mg/dl

Plasma Aldosterone 38 ng/dl (normal: 1-21)

Plasma Renin Activity < 0.6 ng/ml/hr (normal: 0.6-4.3)

What do you recommend now?

1. Stop current medications. Repeat aldosterone and renin levels
2. Confirmatory testing: measure aldosterone after saline infusion
3. Abdominal CT scan
4. Adrenal vein sampling

**Case**

A 31 year old man has hypertension which remains elevated on 3 antihypertensive medications. No family history of hypertension. Meds: Ramipril 10 mg, Amlodipine 10 mg, Metoprolol XL 50 mg  
Exam: BP 158/92 P 68 Ht 6'1" Wt 235 lb.

Physical examination is normal otherwise.

Labs: Na 142 mEq/L, K 3.1 mEq/L, Creatinine 0.9 mg/dl

Plasma Aldosterone 38 ng/dl (normal: 1-21)

Plasma Renin Activity < 0.6 ng/ml/hr (normal: 0.6-4.3)

Abdominal CT: 2.6 cm lipid rich left adrenal adenoma


What do you recommend now?

1. Adrenal vein sampling for aldosterone and cortisol
2. CT guided biopsy of left adrenal mass
3. Long-term treatment with an aldosterone receptor antagonist
4. Surgery to remove left adrenal adenoma

**Primary Aldosteronism**


**Primary Aldosteronism**

Pathophysiology



**Primary Aldosteronism**

Main Subtypes



**Primary Aldosteronism**

Which Hypertensive People to Screen

- BP > 150/100 Sustained
- BP > 140/90 on 3 BP Drugs
- BP controlled on ≥ 4 BP Drugs
- Hypokalemia (spontaneous or diuretic induced)
- All hypertensive patients –recommend by many
- Adrenal incidentaloma

Young WF. J Intern Med 2019; 285:126-148.  
Vaidya A. J Clin Endocrinol Metab 2020; 105:3771-83.  
Mehdi A. Cleve Clin J Med 2021; 88(4):221-7.

**Primary Aldosteronism**

Screening Tests

**Random Sample**

- Plasma Aldosterone (PA)
- Plasma Renin Activity (PRA)

**Positive Screen**

- PA > 5 ng/dl and PRA < 1 ng/ml/hr
- PA/PRA Ratio > 20

For Direct Renin Assay  
PRA = Direct Renin / 8

**Primary Aldosteronism**

False Positive Tests do not Occur

Significant ↑ Aldosterone and ↓ Renin

Nothing Else Causes This  
Positive Results = Positive Results

You Can Test Any Patient Any Time  
Without Stopping Medications

Young WF. J Intern Med 2019; 285:126-148.  
Vaidya A. J Clin Endocrinol Metab 2020; 105:3771-83.  
Mehdi A. Cleve Clin J Med 2021; 88(4):221-7.

**Primary Aldosteronism**

False Negative Tests – Medications

↓ Aldosterone/Renin Ratio

Medication	Aldosterone	Renin	ARR
ACE Inhibitor	↓	↑↑	↓
AR Blocker	↓	↑↑	↓
Ca Channel Blocker	→↓	↑	↓
K Wasting Diuretic	→↑	↑↑	↓
K Sparing Diuretic	↑	↑↑	↓

**Primary Aldosteronism**

Medications That Can Be Used During Testing

- Hydralazine
- Prazosin
- Doxazosin
- Terazosin
- Verapamil Slow Release

Young WF. J Intern Med 2019; 285:126-148.  
Vaidya A. J Clin Endocrinol Metab 2020; 105:3771-83.  
Mehdi A. Cleve Clin J Med 2021; 88(4):221-7.

**Primary Aldosteronism**

False Negative Tests – Other Conditions

↓ Aldosterone/Renin Ratio

Condition	Aldosterone	Renin	ARR
Hypokalemia	↓	→ ↑	↓
Pregnancy	↑	↑↑	↓
Renovascular HTN	↑	↑↑	↓
Malignant HTN	↑	↑↑	↓

Young WF. J Intern Med 2019; 285:126-148.  
Vaidya A. J Clin Endocrinol Metab 2020; 105:3771-83.  
Mehdi A. Cleve Clin J Med 2021; 88(4):221-7.

**Primary Aldosteronism**

Confirmatory Testing

**Sodium Loading Tests**

Oral Salt Load (High NaCl Diet x 3 Days)

IV Saline Infusion (2 L NS over 4 Hours)

**Positive Diagnosis**

Oral Salt Load

- 24 hr Urine Aldosterone (3<sup>rd</sup> day) > 12 ug

IV Saline Infusion

- Plasma Aldosterone > 10 ng/dl

Medication Restrictions:  
Spironolactone

**Primary Aldosteronism**

Confirmatory Testing – When Not Needed

All 3 Present

- Spontaneous Hypokalemia
- Plasma Renin Suppressed
- Plasma Aldosterone > 20 ng/dl

Nothing Else Causes This

Young WF. J Intern Med 2019; 285:126-148.  
Vaidya A. J Clin Endocrinol Metab 2020; 105:3771-83.  
Mehdi A. Cleve Clin J Med 2021; 88(4):221-7.


### Primary Aldosteronism Subtype Classification

Only If Surgery is Being Considered

- CT Adrenal Glands – All Patients
- Adrenal Vein Sampling – Many Patients

Young WF. J Intern Med 2019; 285:126-148.  
Vaidya A. J Clin Endocrinol Metab 2020; 105:3771-83.  
Mehdi A. Cleve Clin J Med 2021; 88(4):221-7.

### Primary Aldosteronism Adrenal Vein Sampling



Calculations  
Aldosterone Side to Side Gradient  
Aldosterone to Cortisol Gradient

### Primary Aldosteronism Adrenal Vein Sampling – When Not Needed?

All 3 Present

- Age: < 35 Years
- Plasma Aldosterone: Markedly Elevated
- CT Scan: Unilateral Cortical Adenoma

Young WF. J Intern Med 2019; 285:126-148.  
Vaidya A. J Clin Endocrinol Metab 2020; 105:3771-83.  
Mehdi A. Cleve Clin J Med 2021; 88(4):221-7.

### Primary Aldosteronism Evaluation and Management

PA > 5 ng/dl and ARR > 20

```


    graph TD
      A[PA > 5 ng/dl and ARR > 20] -- Needed --> B[Confirmatory Testing]
      A -- Not If --> C[Spontaneous ↓ K  
Suppressed Renin  
Aldosterone > 20 ng/dl]
      B --> D[CT Adrenal]
      D -- Needed --> E[Adrenal Vein Sampling]
      D -- Not If --> F[Age < 35  
PA Markedly ↑  
Cortical Adenoma]
      E -- Bilateral --> G[Medical Therapy]
      E -- Unilateral --> H[Adrenalectomy]
    
```

Adapted from: Funder J, J Clin Endocrinol Metab. 2016;101(5):1889-1916

### Primary Aldosteronism Bilateral Adrenal Hyperplasia - Medical Treatment

Mineralocorticoid Receptor Antagonists (MRA) Plus Additional BP Meds as Needed

ACE-I  
ARB  
CCB




MRA: Spironolactone +/- Eplerenone

MRA Doses Sufficient to Maintain K in Upper 1/2 Normal Range Without K Supplements

### Primary Aldosteronism Aldosterone Producing Adenoma – Surgery (+ Pre-op)

Pre-Operative: MRA Then Adrenalectomy



MRA: Spironolactone +/- Eplerenone

MRA Doses Sufficient to Maintain K in Upper 1/2 Normal Range Without K Supplements

**Case**

A 21 year old man present with recent onset of hypertension and headaches. He also acknowledges having intermittent palpitations and episodes of profuse sweating. He informs you that his sister had similar symptoms and a rare adrenal tumor was found.

Medications: None

Exam: BP 178/98 P 88 Ht 5'8" Wt 171 lb

Physical examination is normal otherwise.

You decide to evaluate for causes of secondary hypertension.


What initial tests would have the highest yield?

1. Plasma metanephrines
2. Plasma aldosterone and plasma renin activity
3. 24 hour urine cortisol excretion
4. Renal artery doppler ultrasound

**Pheochromocytoma  
Paraganglioma**

**Pheochromocytoma / Paraganglioma**

Pathophysiology



**Pheochromocytoma / Paraganglioma**

General

Prevalence is Low

1/1,000-10,000 of Hypertensive Patients


Frequently Sought, but Rarely Present

1/200 of Those Investigated

Pheochromocytoma Not Difficult to Find

Majority > 4 cm, Round, HU > 20

Paraganglioma May Take More Investigation



**Pheochromocytoma / Paraganglioma**

Familial Syndromes: 30-40% are Inherited

- Multiple Endocrine Neoplasia Type 2A/2B
- Von Hippel Lindau Syndrome
- Neurofibromatosis Type 1
- Succinate Dehydrogenase Mutations

Genetic Testing is Indicated in All Patients

**Pheochromocytoma / Paraganglioma**

Malignancy Rate: 15-25%

- Malignant Diagnosis Cannot be Made by Histology
- Diagnosis Only Made When Metastases Appear
- Some Mutations Predictive (SDH B)
- Latency May Be Up To 20 Years

Hamidi O. J Clin Endocrinol Metab 2017; 102:3296-3305

**Pheochromocytoma / Paraganglioma**

Which Hypertensive Patients Should Be Screened?

- Headaches, Sweating, Palpitations
- Severe or Resistant Hypertension
- Familial Syndrome
- Adrenal Incidentaloma with HU > 10

**Pheochromocytoma / Paraganglioma**

Diagnostic Tests

Test	Sporadic	Hereditary
	Sensitivity / Specificity	Sensitivity / Specificity
Plasma Metanephrine	99% / 82%	97% / 96%
Urine Metanephrine (24H)	97% / 45%	96% / 82%
Plasma Catecholamine	92% / 72%	69% / 89%
Urine Catecholamine (24H)	91% / 75%	79% / 96%
VMA (24H)	77% / 86%	46% / 99%

**Best Tests**

- Plasma Metanephrine
- Urine Metanephrine (24H)

Adapted from: Lenders JW, JAMA 2002;287:1427-34

**Pheochromocytoma / Paraganglioma**

Diagnostic Tests – True Positives

**Plasma Metanephrine**

2-4 Fold > Ref Range

**Urine Metanephrine**

3-5 Fold > Ref Range

**Pheochromocytoma / Paraganglioma**

Diagnostic Tests – False Positives

**Mild Elevations**

**Especially Common**

- Mildly ↑ Norepinephrine
- Mildly ↑ Normetanephrine

**Pheochromocytoma / Paraganglioma**

False Positive Tests – Medications

Drug	Plasma		Urine	
	NMN	MN	NMN	MN
MAO Inhibitors	++	++	++	++
Cocaine	++	+	++	+
Acetaminophen	++	--	++	--
Methyldopa	++	--	++	--
Phenoxylbenzamine	++	--	++	--
Sulfasalazine	++	--	++	--
Tricyclics	++	--	++	--
Levodopa	+	+	++	+
Sympathomimetics	+	+	+	+
Buspirone	--	++	--	++
Labetalol	--	--	++	++
Sotalol	--	--	++	++

### Pheochromocytoma / Paraganglioma

#### False Positive Tests

#### Other Medications and Situations That May Cause False Positives

- Serotonin Norepinephrine Reuptake Inhibitors
- Selective Serotonin Reuptake Inhibitors
- Ethanol Abuse and Withdrawal
- Clonidine Withdrawal

### Adrenal Masses

#### CT Imaging

#### Benign Conditions

	NCCT	CCT	DCECT	RWP
Adenoma	< 10 HU	Enhances	< 30 HU	> 50%
Pheochromocytoma	> 20 HU	Indeterminate	> 30 HU	< 50%
Myelolipoma	Visible Fat	Visible Fat	Visible Fat	

NCCT = Non Contrast CT – HU  
CCT = Contrast CT  
DCECT = Delayed Contrast Enhanced CT  
RWP = Relative Washout Percentage

### Pheochromocytoma / Paraganglioma


#### Treatment

#### Pre-Operative

Alpha Blocker (1<sup>st</sup>)  
Beta Blocker (2<sup>nd</sup>) or  
Calcium Channel Blocker

Then

#### Adrenalectomy



#### Treatment Effects


BP Control  
Volume Expansion  
Vasodilation  
Rate Control



#### Paraganglioma Surgery


## Adrenal Imaging

### Normal Adrenal Glands



- Normal body size (X): 5-8 mm
- Normal limb size (Y): 2-3 mm
- Total gland width: 2-3 cm

### Normal Adrenal Glands



**Adrenal Imaging**

**Lipid Content**

**CT Scan (Non-Contrast) – Hounsfield Units (HU)**

**Low HU: High Lipid Content = Benign**

- Non-Functioning Adenoma
- Cortisol Producing Adenoma
- Aldosterone Producing Adenoma

**High HU: Low Lipid Content = Benign or Malignant**

- Lipid Poor Adenoma
- Pheochromocytoma
- Adrenal Carcinoma
- Metastatic Carcinoma

**MRI: Signal Drop Out = Benign**

**Adrenal Imaging**

**Evaluation**

**Low HU: High Lipid Content = Benign**

- Overnight 1 mg Dexamethasone Suppression Test
- Plasma Aldosterone and Renin

**High Low Lipid: High HU = Benign or Malignant**

- Overnight 1 mg Dexamethasone Suppression Test
- Plasma Aldosterone and Renin
- Plasma Metanephrines
- Examine Image for Features of Carcinoma

**MRI: Signal Drop Out = Benign (same as above)**

**Case**

A 42 year old woman complains of weight gain, fatigue, muscle weakness, and abnormal menses.

Medications: None

Exam: BP 140/90 P 76 Ht 5'4" Wt 155 lb.

Central obesity, facial plethora and rounding, fullness of supraclavicular fat pads, and purple abdominal striae.

Labs: K 3.6 mEq/L, Na 142 mEq/L, Creatinine 0.8 mg/dl

You decide to evaluate for causes of secondary hypertension.

What initial evaluation would have the highest yield?

1. Plasma ACTH
2. AM serum cortisol
3. 24 hour urine cortisol excretion
4. AM serum cortisol and Plasma ACTH

**Case**

A 42 year old woman complains of weight gain, fatigue, muscle weakness, and abnormal menses.

Medications: None

Exam: BP 140/90 P 76 Ht 5'4" Wt 155 lb.

Central obesity, facial plethora and rounding, fullness of supraclavicular fat pads, and purple abdominal striae.

Labs: K 3.6 mEq/L, Na 142 mEq/L, Creatinine 0.8 mg/dl

Urine cortisol 354 ug/24 hr (nl, 10-60)

What do you recommend now?

1. Plasma ACTH
2. Midnight salivary cortisol
3. MRI pituitary
4. CT abdomen

**Case 4**

A 42 year old woman complains of weight gain, fatigue, muscle weakness, and abnormal menses.

Medications: None

Exam: BP 140/90 P 76 Ht 5'4" Wt 155 lb.

Central obesity, facial plethora and rounding, fullness of supraclavicular fat pads, and purple abdominal striae.

Labs: K 3.6 mEq/L, Na 142 mEq/L, Creatinine 0.8 mg/dl

Urine cortisol 354 ug/24 hr (nl, 10-60)




Plasma ACTH 45 pg/ml (normal: 10-85)

What is the most likely underlying disorder?

1. Ectopic ACTH syndrome
2. Iatrogenic Cushing's syndrome
3. Pituitary ACTH secreting tumor
4. Cortisol producing adrenal adenoma

**Cushing's  
Syndrome**





### Cushing's Syndrome Screening

<u>Screening Tests</u>	<u>Positive Result</u>
• 24 Hour Urine Cortisol	Elevated ( $\geq 2 \times$ nl)
• Bedtime Salivary Cortisol	Elevated
• 1 mg DST*	Cortisol $> 1.8$ ug/dl

\*DST = Dexamethasone Suppression Test  
Take: 1 mg Dex at 10-11 PM  
Measure: serum cortisol next morning at 8:00 AM

Nieman L, J Clin Endocrinol Metab 2008; 93:1526-40  
Endocrine Society Clinical Practice Guidelines

### Cushing's Syndrome Differential Diagnosis

<u>Condition</u>	<u>ACTH (Plasma)</u>	<u>DST (8 mg)</u>
<b>Pituitary ACTH Secreting Tumor</b>	Normal/High	Suppression
<b>Ectopic ACTH Secreting Tumor</b>	High/Very High	No Suppression
<b>Adrenal Cortisol Secreting Tumor</b>	Low	No Suppression


Nieman L, J Clin Endocrinol Metab 2008; 93:1526-40  
Endocrine Society Clinical Practice Guidelines

## Acromegaly

### Acromegaly Clinical Features



### Acromegaly Clinical Features



### Acromegaly Clinical Features



### Acromegaly Clinical Features

- **Hypertension: Resistant to Therapy**
- **CVD/CHF Mortality: Very High**

Acromegaly. Clinical Practice Guidelines – Endocrine Society  
Katznelson L. J Clin Endocrinol Metab 2014; 99: 3933-51

### Acromegaly Diagnostic Testing

- **IGF-1: Elevated - Best Overall Test**
- **GH During OGTT: Failure to Suppress GH**

Acromegaly. Clinical Practice Guidelines – Endocrine Society  
Katznelson L. J Clin Endocrinol Metab 2014; 99: 3933-51

**Hyperthyroidism**

**Hypothyroidism**

**Thyroid Disorders**

**Hypertension**

**Hyperthyroidism**

- Systolic Hypertension

**Hypothyroidism**

- Diastolic Hypertension

McDermott MT. Ann Intern Med 2009; 151 (11):ITC61  
McDermott MT. Ann Intern Med 2012; 157:ITC-1-14.

**Thyroid Function Testing**

**Screening / Case Finding**

**TSH**

**↓ TSH**

**Hyperthyroidism**

**Free T4  
Total T3**

**↑ TSH**

**Hypothyroidism**

**Free T4**

McDermott MT. Ann Intern Med 2009; 151 (11):ITC61  
McDermott MT. Ann Intern Med 2012; 157:ITC-1-14.

**Thank You**

